O013 Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin-2 receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia

por Yee, B, Chapman, J, Grunstein, R, Argent, C, D’Rozario, A, Hopkinson, C, Ramos, J, Landry, I, Yagoda, S, Rege, B
Publicado 2023